New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse
Open Access
- 4 December 2019
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (12) , 1655-1660
Abstract
In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes. A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclinical mouse tumor xenograft model. Compounds displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.Keywords
This publication has 16 references indexed in Scilit:
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaBlood, 2018
- DOT1L and H3K79 Methylation in Transcription and Genomic StabilityBiomolecules, 2018
- Mixed-Lineage Leukemia Fusions and Chromatin in LeukemiaCold Spring Harbor Perspectives in Medicine, 2017
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaBlood, 2013
- Chromatin modifications as therapeutic targets in MLL-rearranged leukemiaTrends in Immunology, 2012
- The Pathogenesis of Mixed-Lineage LeukemiaAnnual Review of Pathology: Mechanisms of Disease, 2012
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L InhibitorCancer Cell, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- The molecular biology of mixed lineage leukemiaHaematologica, 2009
- H3K79 Methylation Profiles Define Murine and Human MLL-AF4 LeukemiasCancer Cell, 2008